Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.35 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064331 | 0.91 | CACNA1H (0.45) | POLBCACNA1HAOC3RIPK1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL3054195 | 0.86 | CACNA1H (0.42) | POLBCACNA1HAOC3RIPK1CYP3A4 | |
| SCHEMBL3060787 | 0.83 | CYP3A4 (0.43) | NR1H2NR1H3POLBCACNA1HAOC3 | |
| SCHEMBL4736030 | 0.83 | CACNA1H (0.47) | MAPK14CACNA1HAOC3CYP3A4LTB4R2 | |
| SCHEMBL3063271 | 0.82 | RIPK1 (0.49) | CACNA1HAOC3RIPK1LTB4R2BCL2A1 | |
| SCHEMBL3056261 | 0.82 | POLB (0.41) | POLBCXCR2CACNA1HRIPK1CYP3A4 | |
| SCHEMBL3058165 | 0.80 | CNR2 (0.51) | RIPK1LTB4R2BCL2A1CNR2 | |
| SCHEMBL3056296 | 0.80 | POLB (0.39) | POLBCACNA1HRIPK1CYP3A4LTB4R2 | |
| Hydrochloric Acid SCHEMBL3053700 | 0.79 | CNR2 (0.50) | RIPK1LTB4R2BCL2A1CNR2 | |
| SCHEMBL3066257 | 0.79 | RIPK1 (0.39) | POLBCACNA1HAOC3RIPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | claimed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | NR1H2 544/4885NR1H3 662/4885POLB 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.